Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 7/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27091771 | 0.91 | DDB1 (0.50) | DDB1CRBNNAMPTKDM4EMAPT | |
| SCHEMBL30087031 | 0.87 | DDB1 (0.52) | DDB1CRBNNAMPTKDM4EMAPT | |
| SCHEMBL22119581 | 0.87 | DDB1 (0.52) | DDB1CRBNNAMPTKDM4EMAPT | |
| SCHEMBL24480492 | 0.86 | GPR119 (0.66) | DDB1CRBNMAPTGPR119 | |
| SCHEMBL23120993 | 0.85 | GPR119 (0.54) | DDB1CRBNHRH3GPR119 | |
| SCHEMBL31444063 | 0.84 | KDM4E (0.47) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL29264315 | 0.84 | DDB1 (0.53) | DDB1CRBNNAMPTKDM4EMAPT | |
| SCHEMBL27091618 | 0.84 | NAMPT (0.52) | DDB1CRBNNAMPTKDM4EMAPT | |
| SCHEMBL31323783 | 0.84 | DDB1 (0.46) | DDB1CRBNHRH3 | |
| SCHEMBL22119507 | 0.84 | DDB1 (0.59) | DDB1CRBNNAMPTMAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-12139492-B2 | Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase | ENDOTARGET INC. | 2024-11-12 | — | — | US | disclosed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| WO-2024141052-A1 | ESTROGEN-RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118271284-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021255212-A1 | BRAF DEGRADERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| EP-3897631-A1 | TARGETED PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113453679-A | Targeted protein degradation | C4医药公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | DDB1 716/4885CRBN 17/4885NAMPT 4868/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | DDB1 425/4885CRBN 32/4885NAMPT 4414/4885 |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | DDB1 612/4885CRBN 241/4885NAMPT 2821/4885 |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | STUB1, MDM2, UBE3A | DDB1 219/4885CRBN 55/4885NAMPT 3483/4885 |
| US-12139492-B2 | Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase | BTK, BCL6B, BCL9 | DDB1 282/4885CRBN 5/4885NAMPT 3278/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | DDB1 219/4885CRBN 55/4885NAMPT 3483/4885 |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | DDB1 729/4885CRBN 166/4885NAMPT 3989/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | DDB1 433/4885CRBN 193/4885NAMPT 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.